Aerie’s glaucoma eye drops win early FDA nod

Aerie Pharmaceuticals (NSDQ:AERI) won an early FDA nod for its glaucoma drug, Rhopressa. The agency was slated to make a decision about the company’s eye drops in February.

The win for Aerie came after an expert panel voted 9-1 in the drug’s favor. Studies have found that Rhopressa lowers elevated intraocular pressure in the eye, but analysts have noted that the twice-daily generic timolol ophthalmic solution 0.5% is more effective for patients with severe cases of glaucoma.

Get the full story at our sister site, Drug Delivery Business News.

The post Aerie’s glaucoma eye drops win early FDA nod appeared first on MassDevice.

from MassDevice http://ift.tt/2klXHZ1